Skip to content

B cell phenotyping in malaria patients

B cell phenotyping, TLR4 expression determination, anti-parasite antibody profiling of serum samples and epidemiological data collection of patients diagnosed with malaria and comparison with healthy controls and non malarial-fever participants at a tertiary referral centre

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/012087
Enrollment
300
Registered
2018-02-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Malaria Patients(P vivax and P falciparum) Non malaria patients Healthy volunteers

Interventions

Intervention1: B cell phenotyping: Through this hypothesis generating study we hope to establish if there is a disturbance in the peripheral B cell subsets of patients suffering an acute episode of vi

Sponsors

Tata Institute of Fundamental Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Females and males of age 5 and above and upto the age of 70 years with clinically suspected malaria on treatment with antimalarials and/or uncomplicated symptomatic malaria (proven) as indicated by the presence of blood smears positive for P falciparum or P. vivax asexual parastemia Participants (living/working with the malaria patients) of either gender with age more than 18 and upto a maximum of 70 years Participants of either gender with age more than 18 (upto a maximum of 70 yers) and suffering from non- malarial fever Willing to participate in this study and ability to comply with the study protocol

Exclusion criteria

Exclusion criteria: Inability to comprehend or unwillingness to follow the study protocol. Complicated malaria patients ( patients with cerebral malaria multiple organ dysfunction severe anemia)

Design outcomes

Primary

MeasureTime frame
Percentage of B cell subsets TLR4 expression and antiparasite antibody profiles on day 1 (main) and day 30 (preferably)Timepoint: Blood collection will be done on Day 1 and Day 30

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr Nithya Gogtay

Department of Clinical Pharmacology GSMC and KEM hospital

njgogtay@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026